Biocon Biologics secures multiple market access agreements for Yesintek

Biocon Biologics (BBL), subsidiary of Biocon, today announced the Company has secured multiple market access agreements for Yesintek (ustekinumab-kfce), its biosimilar to Stelara (ustekinumab). The market access agreements from numerous plans represent over 100+ million lives in the United State.
Express Scripts has added YESINTEK to the National Preferred Formulary (NPF) effective March 21, 2025. Cigna has added YESINTEK to its commercial formulary beginning on March 21, 2025. UnitedHealthcare has added YESINTEK to several formularies including commercial beginning May 1, 2025; managed Medicaid beginning March 1, 2025; and Medicare beginning June 1, 2025. CVS Health has added YESINTEK beginning July 1, 2025. And finally, Optum Rx has added YESINTEK to its Premium and Select formularies beginning July 1, 2025.
YESINTEK has also been selected on several other formularies, including Navitus, Costco Health Solutions, MedImpact, Priority Health, University of Pittsburgh Medical Center (UPMC), and several other regional health plans. Additionally, YESINTEK has been selected as the exclusive Ustekinumab by Blue Cross Blue Shield of Michigan (BCBSM), Florida Healthcare Plan, and several closed-door health systems.
The Company is also finalizing formulary agreements with other commercial carriers.
YESINTEK is approved for the treatment of Crohn's disease, ulcerative colitis, plaque psoriasis and psoriatic arthritis, increasing patient access to more cost-effective treatment options for use in the treatment of common chronic autoimmune diseases. YESINTEK is available in all the same formulations currently provided by STELERA . The available presentations are 45 mg/0.5 mL PFS, 90 mg/mL PFS, 45 mg/0.5 mL vial, and 130 mg/26 mL vial.

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Business Standard

4 hours ago

• Business Standard

Decision on merger with Biocon Biologics soon, says Siddharth Mittal

We are talking about the GLP-1 opportunity and our strong franchise in insulins. There is a huge demand in the global diabetes-obesity segment, said Siddharth Mittal Sohini Das Mumbai Listen to This Article Biocon successfully raised ₹4,500 crore through a qualified institutional placement (QIP) last week that saw strong interest from both Indian and global investors. It is also considering a merger of Biocon Biologics with Biocon to tap into business and scientific synergies rather than listing Biocon Biologics. In a virtual interaction with Sohini Das, Siddharth Mittal, chief executive officer (CEO) and managing director (MD) of Biocon outlined his plans. Edited excerpts: Your QIP was successful. What do you plan to do with the proceeds? There was very strong investor demand. The Board had approved raising up to ₹4,500 crore in one,

Time of India

5 hours ago

• Time of India

US abortion rates rise three years after Dobbs' new ruling on Roe vs Wade, here's why

Three years after the Supreme Court's Dobbs decision overturned Roe v. Wade , the U.S. finds itself at the epicenter of a new abortion battle, one that's defying expectations and reshaping the strategies of both pro-life and pro-choice movements. Despite the pro-life victory in the courts, abortion rates have not dropped; instead, they've remained steady or even increased, raising provocative questions about the true impact of legal bans and the future of reproductive rights in America. The next big fight for abortion opponents is the organisation Planned Parenthood, the nation's leading provider and advocate of affordable sexual and reproductive health care, operates nearly 600 health centers across the country. The unexpected rise: Abortion rates defy pro-life predictions Contrary to pro-life hopes, the number of abortions in the U.S. has not declined post-Dobbs. Recent data from the Charlotte Lozier Institute shows over 1.1 million abortions occurred from July 2023 to June 2024, matching or exceeding pre-Dobbs levels. This estimate, based on the most comprehensive aggregation of clinic, hospital, and virtual provider data, highlights a resilient demand for abortion services even as legal landscapes shift. Researchers caution, however, that the true number may be even higher, as the U.S. lacks a federal abortion reporting mandate and medication abortions, especially those facilitated by international mail-order, are difficult to track with precision. The new battlefield: Pills, politics and laws The unexpected resilience of abortion rates is largely driven by the rise of medication abortion . With the FDA's approval for mail-order mifepristone, telehealth and shield laws have enabled access even in states with bans, and up to 20% of abortions in 2024 were provided via telehealth under such protections. This has allowed patients to bypass state restrictions, fueling what pro-life leaders call a "direct assault on the sovereignty of states." Live Events Pro-life advocates are now focusing on new priorities in response to these trends. Their big challenges, they say, include weakening Planned Parenthood, by targeting its funding streams. Restricting access to abortion pills remains a top objective, as does investing in supportive political candidates and ballot initiatives. Some pro-life lawmakers believe there is a strong chance of defunding Planned Parenthood through a broader reconciliation bill in Congress, which would block Medicaid funds for organizations performing abortions except in cases of rape, incest, or threats to the mother's life. Planned Parenthood, responding to these legislative moves, warned in a statement after the bill passed the Republican-led House in May that such provisions would cut off funding for a range of services beyond abortion, potentially forcing about 200 of its 600 locations to close. "If this bill passes, people will lose access to essential, often lifesaving care — cancer screenings, birth control, STI testing, and yes, abortion," the organization said. Meanwhile, other pro-choice groups are leveraging "shield laws" and ballot initiatives to protect and expand access, turning some states into abortion havens while others enforce near-total bans.

Time of India

3 days ago

• Time of India

Inside the Texas Children's Hospital trans care whistleblower case: One year of fallout and unanswered questions

Credit: X/Vanessa Sivadge It's been exactly one year since nurse Vanessa Sivadge ignited a political and legal firestorm by accusing Texas Children's Hospital—America's largest pediatric care center—of secretly continuing gender transition treatments for minors in violation of state law. What began as a whistleblower interview has since spiraled into FBI visits, criminal indictments, legislative inquiries, and the quiet departure of a once-revered CEO. Here's how the case unfolded and what has happened since the revelations came to light. June 2024: Vanessa Sivadge goes public On June 23, 2024, the New York Post published an interview with Vanessa Sivadge, 31, a former nurse at Texas Children's Hospital (TCH). In the interview, Sivadge alleged that doctors at TCH continued to perform gender-affirming care on minors despite state law and public assurances that the program had been shut down. 'These doctors are driven by a political agenda, like an ideological agenda,' she told the Post. 'And I truly believe that they think that they're doing the right thing.' She further alleged that doctors manipulated parents into consenting to medical transition by invoking suicide threats. 'Parents were manipulated by doctors with an ideological agenda to go down this path of medical transition for their child,' she said. 'And I do think that doctors would use manipulative language to suggest that if they didn't do this their child would commit suicide or they would harm themselves.' According to Sivadge, doctors bypassed Texas' Medicaid restrictions by misdiagnosing minors with hormone deficiencies so that puberty blockers and hormone therapies would be covered. 'There was just no discussion of what are the risks, what are the long-term effects,' she said. 'Many of [the patients] had previous ER visits for attempted suicide, many of them are autistic, many of them are depressed and anxious, and that's really devastating because it's really clear there's something else going on.' The FBI shows up Following her public disclosures, Sivadge said she was visited by two FBI agents. Video footage shared by Christopher Rufo on X (formerly Twitter) shows two plainclothes agents at her door. One agent can be heard saying: 'I'm sure you're aware of some of the things that have been going on at your work lately.' Sivadge told Rufo, 'They threatened me. They promised they would make life difficult for me if I was trying to protect the leaker. They said I was not safe at work and claimed that someone at my workplace had given my name to the FBI.' Sivadge's revelations came a year after Dr. Eithan Haim, a surgeon at the hospital, released documents in May 2023 showing that Texas Children's continued providing gender-affirming care after claiming it had ceased operations in March 2022. Haim was later indicted by the Department of Justice on four federal charges—three of them for HIPAA violations. Haim denied any wrongdoing. 'They wanted to intimidate me into silence using every technique the federal leviathan had at their disposal. But they failed,' Haim said. 'The only way to lose is to submit to corruption. It's time to fight back harder than ever!' Haim claimed the leaked files did not contain personal health information. And like Haim, Sivadge also had to pay the price for bringing the truth out in the open. Sivadge in a tweet revealed she had been fired in August 2024, just two months after coming forward. 'I had low expectations when I went public, doubtful and uncertain if anyone would notice or care,' she wrote. 'Imagine my shock when people I had never met overwhelmed my Legal Defense Fund with financial support.' She added: 'After I was fired in August 2024, these early contributions by generous supporters enabled us to retain [@BurkeLawTweets] as our legal counsel. They are the most qualified, tenacious group of attorneys I have ever had the privilege of working with.' However, Sivadge points out that the two journalists she accused,- David Pauls and Dr Richard O Roberts- have since vanished from the scene. Jonathan Choe, a reporter known for investigating gender medicine practices, visited the physicians' listed residences. Despite attempts to make contact, neither doctor was found at home, and no public statement has been issued by them regarding the allegations to date. Amidst the controversy, the CEO of the Texas hospital, Mark A. Wallace, stepped down after 35 years at the helm. The announcement was delivered without fanfare and did not reference the whistleblower case or ongoing investigations. Credit: X/Vanessa Sivadge However, internal memos obtained by reporters showed that Wallace had previously circulated communications stating that the hospital's gender program had been fully shut down following the February 2022 directive from Attorney General Ken Paxton, which categorized gender-affirming care for minors as potential child abuse under Texas law. Contrary to those assurances, whistleblower claims and leaked documents showed that the program had continued operations in various capacities well into 2023, with medical records indicating the ongoing prescription of puberty blockers and hormones. The disconnect between internal messaging and actual medical practice is now a focal point in both legal and legislative reviews of the hospital's conduct. June 2025: One year later, still no closure The Texas Attorney General's Office, under Ken Paxton, is actively investigating the allegations involving Medicaid fraud and misrepresentation of gender-related diagnoses for billing purposes. State Rep. Brian Harrison and Sen. Mayes Middleton submitted a joint letter urging Texas Health and Human Services to conduct a full audit of Medicaid/CHIP funds used by Texas Children's Hospital from 2021 onward. Credit: X/Vanessa Sivadge In their statement, they wrote: 'There is perhaps no more important responsibility we all share than to be good stewards with tax dollars... If true, not only do the actors involved know they are perpetrating a fraud, but they are doing it to engage in child abuse.' Meanwhile, federal prosecutors continue their case against Dr. Eithan Haim. He faces four charges—three for alleged HIPAA violations and one for unauthorized access of medical files. Haim maintains that no protected health information was leaked and that his actions were protected whistleblowing under federal law. Texas Attorney General Ken Paxton has since launched an official investigation into the hospital's use of Medicaid funds and the allegations of child abuse. State Rep. Brian Harrison has called for emergency hearings. Meanwhile, Dr. Eithan Haim's legal case continues, as does fundraising for both whistleblowers' legal defenses. For her part, Vanessa Sivadge remains defiant and resolute. 'They tried to silence me,' she said. 'But if telling the truth costs me everything, I can live with that.' One step to a healthier you—join Times Health+ Yoga and feel the change